Managing Bone Disease in Kidney Transplant Recipients

Share this content:
To start this activity, click Begin at the bottom of this pageManaging Bone Disease in Kidney Transplant Recipients

Release Date: May 2012

Expiration Date: May 2013

Estimated time to complete the educational activity: 1 hour

This activity is jointly sponsored by Medical Education Resources and Haymarket Media, Inc.

Statement of Need: Bone disease is a well-known complication in kidney transplant recipients, who experience a raid loss of bone mass, especially during the early post-transplant period. The management of this bone loss often is insufficient and nephrologists and other clinicians involved in the care of renal transplant recipients need to understand mineral bone disease (MBD) in these patients and be aware of the various treatment options available to prevent bone loss.

Target Audience: This activity has been designed to meet the education need of nephrologists and other clinicians involved in the care of renal transplant recipients.

Educational Objectives: After completing the activity, the participant should be better able to:

  • Explain the major factors that contribute to MBD, including the effects of transplantation-related treatment.
  • Review appropriate therapeutic options to manage bone loss after renal transplantation.

Accreditation Statement:This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest: Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

Name of Faculty Reported Financial Relationship
Miklos Z. Molnar, MD, PhD No financial relationships to disclose
Kamyar Kalentar Zadeh, MD, MPH, PhD Grants/Research Support: NIH, NKF, Abbott, Shire
Consultant: NIH, Abbott, Amgen, DaVita, Fresenius-Kabi, Genzyme, Otsuka, Shire, Vifor
Speakers' Bureau: Abbott, Amgen, Fresenius-Kabi, Otsuka, Shire /td>

The content managers, Jody A. Charnow and Marina Galanakis, of Haymarket Media, Inc., and Julie Johnson, PharmD, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest.

Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period May 2012 through May 2013, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at www.myCME.com/renalandurologynews, and 4) complete the evaluation form online.< /p>

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Page 1 of 5
You must be a registered member of Renal and Urology News to post a comment.